Artivion (NYSE:AORT - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect Artivion to post earnings of $0.11 per share and revenue of $107.96 million for the quarter.
Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). The firm had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Artivion Price Performance
AORT stock traded up $0.67 during midday trading on Monday, reaching $31.59. 36,449 shares of the stock were exchanged, compared to its average volume of 417,281. The company has a fifty day moving average price of $30.31 and a 200 day moving average price of $27.90. The stock has a market capitalization of $1.35 billion, a PE ratio of -63.25 and a beta of 1.64. Artivion has a 52 week low of $21.97 and a 52 week high of $32.94. The company has a debt-to-equity ratio of 1.08, a current ratio of 5.53 and a quick ratio of 3.95.
Insider Buying and Selling
In other news, SVP Marshall S. Stanton sold 15,000 shares of the stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $29.50, for a total value of $442,500.00. Following the sale, the senior vice president owned 64,200 shares in the company, valued at $1,893,900. This represents a 18.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean F. Holloway sold 8,748 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total value of $253,692.00. Following the sale, the senior vice president owned 178,510 shares in the company, valued at $5,176,790. This trade represents a 4.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,954 shares of company stock valued at $2,108,525 in the last ninety days. 8.10% of the stock is owned by company insiders.
Hedge Funds Weigh In On Artivion
A number of hedge funds have recently made changes to their positions in AORT. Royal Bank of Canada lifted its holdings in Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company's stock worth $952,000 after buying an additional 20,010 shares in the last quarter. AQR Capital Management LLC lifted its stake in Artivion by 8.8% in the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company's stock valued at $862,000 after buying an additional 2,823 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Artivion by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company's stock worth $580,000 after acquiring an additional 1,032 shares during the period. Institutional investors and hedge funds own 86.37% of the company's stock.
Wall Street Analysts Forecast Growth
AORT has been the subject of several recent research reports. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and set a $32.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. JMP Securities reaffirmed a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, May 6th. Finally, Canaccord Genuity Group assumed coverage on Artivion in a research report on Tuesday, June 17th. They issued a "buy" rating and a $35.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $32.40.
Read Our Latest Research Report on Artivion
Artivion Company Profile
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Stories
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access